Journal of Antitrust Enforcement, 2015, 0, 1–41 doi: 10.1093/jaenfo/jnv033 Article Revising the US vertical merger guidelines: policy issues and an interim guide for practitioners Steven C. Salop* and Daniel P. Culley** ABSTRACT While the Horizontal Merger Guidelines issued by US antitrust enforcement agencies have been periodically revised since their first publication in 1968, the Vertical Merger Guidelines were last the subject of modification in 1984. Moreover, there appears to be little appetite within the agencies for revision; so interested parties are for the mo- ment left with guidance which does not reflect contemporary economic theory, agency practice or the 2010 Horizontal Merger Guidelines. The aim of this article is to par- tially fill the gap left by this divergence, by providing both a modern analytical frame- work for the assessment of vertical mergers and illustrative examples of recent antitrust agency enforcement actions upon which practitioners and agency staff alike may rely. The article also identifies a number of legal and policy issues which would need to be considered were the Vertical Merger Guidelines to be revised. We hope that this article will facilitate a more rapid revision. KEYWORDS: antitrust, mergers, vertical mergers, enforcement, exclusion, efficiencies JEL CLASSIFICATIONS: K00, K21, K40
I. INTRODUCTION Mergers and acquisitions are a major component of antitrust law and practice. The US antitrust agencies spend a majority of their time on merger enforcement. The focus of most merger review at the agencies involves horizontal mergers, that is, mer- gers among firms that compete at the same level of production or distribution. Horizontal mergers may involve situations where both merging firms are actual com- petitors (firms that currently compete in the market). However, horizontal mergers can also involve situations where one or both of the firms currently are not actual competitors, but are potential competitors.1
* Professor of Economics and Law, Georgetown University Law Center; Senior Consultant, Charles River Associates. Email: [email protected] ** Associate, Cleary Gottlieb Steen & Hamilton, LLP. Email: [email protected] 1 One or both firms can be potential competitors for a product that has not yet been entered the market, for example, new pharmaceuticals that are still undergoing FDA review to evaluate their safety and efficacy for treatment of a particular disease.
VC The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]